Apr 24, 2008 - Lannett Company, Inc. (AMEX:LCI), a manufacturer of generic pharmaceuticals, today announced that it has received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Dipyridamole Tablets USP, 25mg, 50mg, and 75mg, the generic equivalent of Persantine(R) Tablets manufactured by Boehringer Ingelheim GmbH. According to Wolters Kluwer, total sales of generic Dipyridamole Tablets were $46 million a year in 2007 at average wholesale price (AWP).
Dipyridamole Tablets are indicated as an adjunct to coumarin anticoagulants in the prevention of postoperative thromboembolic complications of cardiac valve replacement.
No comments:
Post a Comment